Marshall Fordyce - 16 Jan 2024 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
16 Jan 2024
Net transactions value
$0
Form type
4
Filing time
18 Jan 2024, 16:54:02 UTC
Previous filing
03 Jan 2024
Next filing
16 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Award $0 +78,750 +31% $0.000000 335,627 16 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (right to buy) Award $0 +292,500 $0.000000 292,500 16 Jan 2024 Class A Common Stock 292,500 $16.80 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service through each vesting date.
F2 1/48 of the shares subject to the stock option will vest and become exercisable on February 16, 2024, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date.